Summit Therapeutics (SMMT) Misses Q2 EPS by 3c
Tweet
Share
E-mail
Get Alerts SMMT Hot Sheet
Join SI Premium – FREE
Summit Therapeutics (NASDAQ: SMMT) reported Q2 EPS of (GBP0.12), GBP0.03 worse than the analyst estimate of (GBP0.09).
For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Anthropic plans IPO potentially exceeding SpaceX's $86B record - Bloomberg
- Walmart (WMT) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY27 EPS Guidance
- HCW Biologics (HCWB) files for 1.24M share offering by selling stockholders
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
